Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018265
Filing Date
2023-11-08
Accepted
2023-11-08 16:05:43
Documents
88
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20230930x10q.htm   iXBRL 10-Q 1956302
2 EX-31.1 adap-20230930xex31d1.htm EX-31.1 9826
3 EX-31.2 adap-20230930xex31d2.htm EX-31.2 10569
4 EX-32.1 adap-20230930xex32d1.htm EX-32.1 6140
5 EX-32.2 adap-20230930xex32d2.htm EX-32.2 6122
6 GRAPHIC adap-20230930x10q002.jpg GRAPHIC 54690
7 GRAPHIC adap-20230930x10q003.jpg GRAPHIC 55869
  Complete submission text file 0001558370-23-018265.txt   8932823

Data Files

Seq Description Document Type Size
8 EX-101.SCH adap-20230930.xsd EX-101.SCH 59735
9 EX-101.CAL adap-20230930_cal.xml EX-101.CAL 68545
10 EX-101.DEF adap-20230930_def.xml EX-101.DEF 231965
11 EX-101.LAB adap-20230930_lab.xml EX-101.LAB 469277
12 EX-101.PRE adap-20230930_pre.xml EX-101.PRE 371088
82 EXTRACTED XBRL INSTANCE DOCUMENT adap-20230930x10q_htm.xml XML 1696731
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 231387772
SIC: 2836 Biological Products, (No Diagnostic Substances)